289 related articles for article (PubMed ID: 27594536)
1. Urinary human chorionic gonadotropin isoform concentrations in doping control samples.
Butch AW; Woldemariam GA
Drug Test Anal; 2016 Nov; 8(11-12):1147-1151. PubMed ID: 27594536
[TBL] [Abstract][Full Text] [Related]
2. Immunoextraction-tandem mass spectrometry method for measuring intact human chorionic gonadotropin, free β-subunit, and β-subunit core fragment in urine.
Woldemariam GA; Butch AW
Clin Chem; 2014 Aug; 60(8):1089-97. PubMed ID: 24899693
[TBL] [Abstract][Full Text] [Related]
3. Urine reference intervals for human chorionic gonadotropin (hCG) isoforms by immunoextraction-tandem mass spectrometry to detect hCG use.
Butch AW; Ahrens BD; Avliyakulov NK
Drug Test Anal; 2018 Jun; 10(6):956-960. PubMed ID: 29098788
[TBL] [Abstract][Full Text] [Related]
4. Estimating the hCGβcf in urine during pregnancy.
Nerenz RD; Butch AW; Woldemariam GA; Yarbrough ML; Grenache DG; Gronowski AM
Clin Biochem; 2016 Feb; 49(3):282-6. PubMed ID: 26541857
[TBL] [Abstract][Full Text] [Related]
5. Falsely decreased human chorionic gonadotropin (hCG) results due to increased concentrations of the free beta subunit and the beta core fragment in quantitative hCG assays.
Grenache DG; Greene DN; Dighe AS; Fantz CR; Hoefner D; McCudden C; Sokoll L; Wiley CL; Gronowski AM
Clin Chem; 2010 Dec; 56(12):1839-44. PubMed ID: 20930131
[TBL] [Abstract][Full Text] [Related]
6. Characterizing urinary hCGβcf patterns during pregnancy.
Nerenz RD; Yarbrough ML; Stenman UH; Gronowski AM
Clin Biochem; 2016 Jul; 49(10-11):777-81. PubMed ID: 27087510
[TBL] [Abstract][Full Text] [Related]
7. Using a simulation model to assess risk of false negative point-of-care urinary human chorionic gonadotropin device results due to high-dose hook interference.
Milhorn D; Korpi-Steiner N
Clin Biochem; 2015 Feb; 48(3):99-104. PubMed ID: 25448030
[TBL] [Abstract][Full Text] [Related]
8. Cross-reaction with luteinizing hormone beta-core is responsible for the age-dependent increase of immunoreactive beta-core fragment of human chorionic gonadotropin in women with nonmalignant conditions.
Iles RK; Javid MK; Gunn LK; Chard T
Clin Chem; 1999 Apr; 45(4):532-8. PubMed ID: 10102914
[TBL] [Abstract][Full Text] [Related]
9. Screening method to evaluate point-of-care human chorionic gonadotropin (hCG) devices for susceptibility to the hook effect by hCG β core fragment: evaluation of 11 devices.
Nerenz RD; Song H; Gronowski AM
Clin Chem; 2014 Apr; 60(4):667-74. PubMed ID: 24463559
[TBL] [Abstract][Full Text] [Related]
10. Comparison of newly developed immuno-MS method with existing DELFIA(®) immunoassay for human chorionic gonadotropin determination in doping analysis.
Lund H; Snilsberg AH; Halvorsen TG; Hemmersbach P; Reubsaet L
Bioanalysis; 2013 Mar; 5(5):623-30. PubMed ID: 23425277
[TBL] [Abstract][Full Text] [Related]
11. Persistently elevated serum concentrations of human chorionic gonadotropin (hCG).
Collazo Abal C; Fernández Marcos MC; Casado Rey P; Vázquez Caamaño MP; Alfthan H; Koistinen H; Stenman UH
Clin Chem Lab Med; 2023 Oct; 61(11):2028-2032. PubMed ID: 37279342
[TBL] [Abstract][Full Text] [Related]
12. The ISOBM TD-7 Workshop on hCG and related molecules. Towards user-oriented standardization of pregnancy and tumor diagnosis: assignment of epitopes to the three-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives.
Berger P; Sturgeon C; Bidart JM; Paus E; Gerth R; Niang M; Bristow A; Birken S; Stenman UH
Tumour Biol; 2002; 23(1):1-38. PubMed ID: 11893904
[TBL] [Abstract][Full Text] [Related]
13. Determination of human chorionic gonadotropin.
Stenman UH; Alfthan H
Best Pract Res Clin Endocrinol Metab; 2013 Dec; 27(6):783-93. PubMed ID: 24275190
[TBL] [Abstract][Full Text] [Related]
14. Importance of the detection method for intact dimeric human chorionic gonadotropin without interference with the free human chorionic gonadotropin beta subunit for pregnancy exclusion before liver transplantation in a woman with cholangiocarcinoma.
Massart C; Lucas C; Rioux-Leclercq N; Fergelot P; Pouvreau-Quillien V; Volatron AC
Clin Chem Lab Med; 2005; 43(8):886-9. PubMed ID: 16217885
[TBL] [Abstract][Full Text] [Related]
15. Analysis of human chorionic gonadotropin (hCG): application of routine immunological methods for initial testing and confirmation analysis in doping control.
Kuuranne T; Ahola L; Pussinen C; Leinonen A
Drug Test Anal; 2013 Aug; 5(8):614-8. PubMed ID: 23303576
[TBL] [Abstract][Full Text] [Related]
16. Immunoprocedures for detecting human chorionic gonadotropin: clinical aspects and doping control.
Stenman UH; Unkila-Kallio L; Korhonen J; Alfthan H
Clin Chem; 1997 Jul; 43(7):1293-8. PubMed ID: 9216477
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of two immunoassays for the measurement of human chorionic gonadotropin in urine for anti-doping purposes.
Robinson N; Sottas PE; Saugy M
Clin Lab; 2010; 56(5-6):197-206. PubMed ID: 20575467
[TBL] [Abstract][Full Text] [Related]
18. hCGbeta core fragment is a metabolite of hCG: evidence from infusion of recombinant hCG.
Norman RJ; Buchholz MM; Somogyi AA; Amato F
J Endocrinol; 2000 Mar; 164(3):299-305. PubMed ID: 10694369
[TBL] [Abstract][Full Text] [Related]
19. Epitope analysis and detection of human chorionic gonadotropin (hCG) variants by monoclonal antibodies and mass spectrometry.
Lund H; Paus E; Berger P; Stenman UH; Torcellini T; Halvorsen TG; Reubsaet L
Tumour Biol; 2014 Feb; 35(2):1013-22. PubMed ID: 24014048
[TBL] [Abstract][Full Text] [Related]
20. Comparison of specific immunoassays for detection of the beta-core human chorionic gonadotrophin fragment in body fluids.
de Medeiros SF; Amato F; Matthews CD; Norman RJ
J Endocrinol; 1992 Oct; 135(1):161-74. PubMed ID: 1279091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
